What Does Wall Street Think About Avantor, Inc. (AVTR)?

Group 1 - Avantor, Inc. (NYSE:AVTR) has been downgraded by Jefferies from Hold to Underperform, with a price target reduced from $12 to $9, citing ongoing margin headwinds and market share losses as significant concerns [1] - BofA also downgraded Avantor from Buy to Neutral on December 15, lowering the price target from $14 to $13, while indicating that 2026 is expected to be the third consecutive year of market normalization, with Life Science Tools headwinds diminishing [2] - Avantor operates in the life sciences tools sector, providing essential services and products to industries such as biopharma, healthcare, and advanced technologies [2] Group 2 - Analysts express caution regarding the potential for Avantor, suggesting that the biggest upside risk in the Tools/CRO markets would be a resurgence in spending by Biopharma [2] - The company is viewed as undervalued, but analysts believe that certain AI stocks may present greater upside potential with less downside risk [3]